lung disease have used a population study approach with genes of interest, or candidate Diffuse (interstitial) lung disease comprises a wide variety of conditions, in-genes, identified prospectively by a knowledge of the pathophysiology of the disease. dividually relatively uncommon but collectively being found in approximately 50 per 100 000 population. Some of these diseases are of known aetiology but others Scientific basis are not. It has been suggested that the The principal candidate genes that have been environment is a major contributory fac-studied in diffuse lung disease have been those tor in this group of diseases. However, encoded by the major histocompatibility comsince not all individuals exposed to a com-plex (MHC) classes I, II, and III. Genes within mon environment develop interstitial dis-the MHC region encode cell surface glycoeases, it can be hypothesised that there is proteins known as the human leucocyte antia genetic predisposition to their de-gens (HLA) which present processed antigens velopment. These diseases cause major to T cells and are highly polymorphic. Immune morbidity and mortality due to lung injury responses are principally driven by T cell reand fibrosis. It follows that, if individuals ceptor (TcR) activation resulting from rewho are genetically predisposed to develop cognition of peptides which are presented as a diseases characterised by lung injury and complex with HLA molecules on the surface fibrosis can be identified, then man-of antigen presenting cells. agement strategies can be designed which will attempt to identify and treat early disease and, in the longer term, to develop   targeted genetic interventional ap-Immune granulomas result from specific cell proaches to treatment. mediated immune mechanisms, although the (Thorax 1997;52:92-94) 
antigen driven disease in which sarcoid-like scleroderma, sarcoidosis, berylliosis.
granulomas are formed in the lungs following inhalation of beryllium salts. Not all individuals exposed to beryllium develop the disease and exposure to relatively small amounts of antigen Diffuse lung diseases may be triggered by known or unknown factors. Environmental risk can cause disease in some individuals. There is an association between HLA-DPB alleles factors include occupational exposure to beryllium, cobalt or asbestos, therapeutic drugs, with a glutamate residue at position 69 of the chain (Glu 69) and development of berylliosis. 2 and radiation. Risk factors also include gender, age, and race. For example, systemic sclerosis HLA-DPB proteins are encoded by genes within the MHC and are involved in presenting occurs predominantly in women (male:female ratio 9:1) whereas sarcoidosis occurs pre-foreign antigens to CD4+ T lymphocytes. The amino acid residue 69 is situated within the dominantly in those in the 30-40 year age range Afro-Caribbean descent than in Caucasians.
and is involved in antigen binding and re-
Environmental
Exposure to similar amounts of environ-cognition by the TcR. This suggests that the genetic predisposition. 1 Most studies of diffuse disease related to antigen presentation. Genes group.bmj.com on May 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from may trigger the same disease in different patients. Additionally, environmental triggers may be refractory to digestion by macrophages and may therefore induce prolonged release of inflammatory mediators which perpetuate the T cell response. Geographical variability may result in the presence of different environmental triggers but also differences in linkage disequilibrium between HLA antigens. There may also be heterogeneity in disease diagnosis resulting in a lack of consistency in terms of disease subsetting.
In a study of patients with systemic sclerosis in association with pulmonary fibrosis it was shown that the presence of the HLA-DR3/ DR52a alleles and/or the anti-Scl-70 autoantibody was a risk factor for the development of pulmonary fibrosis.
6 Similar findings have subsequently been reported in other racial groups and suggest that HLA alleles may be types. [7] [8] [9] within the MHC region are the most likely candidates for this predisposition, although Therapeutic potential studies of the association between these genes One of the more exciting potential benefits of and sarcoidosis have produced disparate res-defining genetic susceptibility to diffuse lung ults. 3 This discrepancy may be attributed to a disease is the identification of patients who are number of factors including obvious ethnic more likely to develop lung disease, especially differences and disease diagnosis or staging. We fibrosis. Early clinical intervention in such cases have recently shown a significant association could be of considerable benefit for the patient. between HLA-DPB Glu 69+ alleles and sar-A good example is the identification and assesscoidosis in a carefully defined population of ment of disease progression in diffuse lung Caucasian patients with sarcoidosis when com-disease found in systemic sclerosis. Autopared with an ethnically matched control popu-antibodies to critical cell antigens are common lation. 4 This suggests that there may be a in systemic sclerosis and the presence of certain common gene or set of genes involved in the autoantibodies has been linked with clinical formation of granulomas. subsets or racial subgroups of patients with Generally, the reported MHC associations systemic sclerosis. 10 This association probably have not been absolute, suggesting that other occurs because the disease subsets result from genes may also be involved. Accumulation of activation of distinct subpopulations of T cells activated T cells at disease sites in sarcoidosis, and stimulate the production of different autoand the functional relationship between the antibodies. This is supported by data that show MHC and the TcR, support the hypothesis that certain MHC alleles are associated with that the genes encoding the TcR are good the development of certain autoantibodies. 11 It candidates to influence the development of is therefore reasonable to suppose that idendiffuse lung disease. There is discordance in tification of a disease subset may be important the results of studies of the clonality of TcR in the instigation of careful monitoring and variable (V) chain families found in diffuse lung potentially more effective treatment. Ultidisease, which is possibly due to differences in mately, genetic transfer technologies may rethe MHC phenotype of the patients studied. verse the biological consequences of the genetic This hypothesis has been tested in a study predisposition. 12 which used a combined MHC, TcR approach in sarcoidosis and showed a very strong concordance between HLA-DR3, DQ2, and the TcR V 2.3 chain. 
Conclusions
In the past decade there have been considerable advances in the assessment of genetic susceptibility to diffuse lung disease. We are now    Diffuse lung disease is one of the most common able to identify genetic polymorphisms and to perform functional studies related to polyfeatures of systemic sclerosis and some degree of fibrosing alveolitis is found in most patients morphisms found in these regions. Consequently, we are in a strong position to identify at post mortem examination. Systemic sclerosis is considered to be an autoimmune disease and and define disease susceptibility in genetic terms, although this clearly requires further population studies have reported conflicting and often relatively weak associations of MHC study and confirmation from different research groups. In addition, the identification of risk with the disease, possibly due to geographical, environmental, and ethnic variability or clinical factors has important implications for the initiation of close disease monitoring and for the heterogeneity. Environmental variability may be important since different causal antigens initiation of appropriate therapy at an early group.bmj.com on May 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from
